Tenalisib
Metastatic Triple-Negative Breast Cancer (TNBC)
Phase 2Active
Key Facts
Indication
Metastatic Triple-Negative Breast Cancer (TNBC)
Phase
Phase 2
Status
Active
Company
About Rhizen Pharmaceuticals
Rhizen Pharmaceuticals is a private, clinical-stage biotech company developing novel small molecule therapeutics for oncology and inflammation. The company has a pipeline with assets in Phase 1 and Phase 2 clinical trials, including Tenalisib for metastatic triple-negative breast cancer (TNBC) and RP12146 for metastatic castration-resistant prostate cancer (mCRPC). Rhizen operates with a capital-efficient model, aiming to progress assets to clinical proof-of-concept before out-licensing to global partners for registration and commercialization. The company emphasizes full intellectual property ownership of its programs.
View full company profile